HCR 555 Module 5 Assignment 4: Globalization, Off-Label Use, Biologics and Counterfeits Example

Medicines Without Borders: Off-Label Use, Biosimilars, Global Supply Chains and the Fight Against Falsified Drugs

Student Name

MS in Regulatory Science, Arizona State University

HCR 555: Pharmaceutical Safety and Risk Management

Instructor Name

Month Day, Year

Medicines Without Borders: Off-Label Use, Biosimilars, Global Supply Chains and the Fight Against Falsified Drugs

Introduction

Regulators control what a label says, who may make a drug and where trials and factories are inspected. Much of pharmaceutical risk today lies just outside those lines. This paper examines four such areas, off-label use, follow-on biologics, globalized research and manufacturing and counterfeit medicines, and proposes measures for each.

Off-Label Use

Once a drug is approved, physicians may prescribe it for conditions, doses or populations the label does not cover. Off-label use can be good medicine, especially in pediatrics and oncology, where trials lag behind practice. But it is common and often poorly supported. Data from U.S. office visits in 2001 showed that roughly a fifth of uses of common drugs were off label, and nearly three quarters of those uses had little or no scientific support (Radley et al., 2006). Manufacturers may not promote off-label uses, and large settlements have followed when they did, but prescribing itself is not restricted.

Follow-On Biologics

Biologics are large molecules made in living cells, and a copy cannot be identical in the way a generic small-molecule drug can. The Biologics Price Competition and Innovation Act of 2009 created an abbreviated pathway for biosimilars, products shown to be highly similar to an approved reference biologic with no clinically meaningful differences, and a further designation of interchangeability that allows pharmacy-level substitution where state law permits (42 U.S.C. § 262(k)). The regulatory concerns are immunogenicity, small manufacturing changes that alter a product over time and naming and tracking that let adverse events be attributed to the right product. The market concerns are the reverse of safety: reference products are marketed heavily and priced high, patent thickets and rebate agreements have delayed biosimilar entry, and slow uptake has limited the savings the law was meant to produce.

Globalization of Trials and Manufacturing

Clinical research has moved overseas because recruitment is faster and costs are lower. By the late 2000s, about a third of Phase 3 trials sponsored by the largest U.S. drug companies were being run entirely outside the United States, and most study sites were abroad (Glickman et al., 2009). The ethical questions include whether participants in lower-income countries give truly informed consent, whether they will have access to the drug once approved and whether results apply to U.S. patients with different genetics, diets and standards of care. Manufacturing has globalized as well, with much of the world's active pharmaceutical ingredient now produced in a small number of countries.

How Globalization Leads to Shortages and Counterfeits

Concentrated supply chains are efficient until something breaks. When a single overseas plant producing a sterile injectable fails an inspection or closes, hospitals can lose access to a drug with few alternatives, and the FDA's review of shortages found that low prices for older generic drugs leave manufacturers little incentive to invest in quality or redundancy (U.S. Food and Drug Administration [FDA], 2019). Shortages, in turn, open the door to counterfeiters, who fill gaps with falsified products sold online or through gray-market distributors. The World Health Organization estimated that about one in ten medical products in low- and middle-income countries is substandard or falsified (World Health Organization [WHO], 2017). Long, multi-country chains make it hard for any one regulator to see where a product has been.

Measures to Combat Counterfeiting

ELSI Appraisal

Ethical

Off-label use without evidence and trials run where participants cannot later obtain the drug both raise questions of fairness to patients and research subjects.

Legal

U.S. law regulates labels, manufacturers and distributors, but not physicians' prescribing choices or foreign factories directly, which leaves gaps that depend on inspection and cooperation.

Social

High biologic prices and drug shortages fall hardest on uninsured patients and safety-net hospitals, and falsified medicines cause the most harm in countries with the weakest regulators.

Proposed Solutions

Fund comparative studies of common off-label uses, speed biosimilar entry by limiting patent thickets and exclusionary rebates, condition approval of foreign-trial data on post-trial access plans and reward manufacturers that maintain redundant, high-quality supply.

Conclusion

Off-label use, biosimilars, global research and counterfeit medicines are separate topics, but they share a structure: each lives at the edge of what a regulator can see. Closing those gaps requires evidence for common uses, competition for expensive biologics, ethical rules for global trials and a supply chain that can be traced from factory to patient.

References

Glickman, S. W., McHutchison, J. G., Peterson, E. D., Cairns, C. B., Harrington, R. A., Califf, R. M., & Schulman, K. A. (2009). Ethical and scientific implications of the globalization of clinical research. New England Journal of Medicine, 360(8), 816-823. https://doi.org/10.1056/NEJMsb0803929

Licensure of biological products as biosimilar or interchangeable, 42 U.S.C. § 262(k) (2024).

Radley, D. C., Finkelstein, S. N., & Stafford, R. S. (2006). Off-label prescribing among office-based physicians. Archives of Internal Medicine, 166(9), 1021-1026. https://doi.org/10.1001/archinte.166.9.1021

U.S. Food and Drug Administration. (2019). Drug shortages: Root causes and potential solutions. https://www.fda.gov/media/131130/download

World Health Organization. (2017). A study on the public health and socioeconomic impact of substandard and falsified medical products. https://www.who.int/publications/i/item/9789241513432